BUSINESS
Dr Reddy's expects to launch Remdesivir in August
On another antiviral Favipiravir, which is prescribed for mild COVID-19 cases, Dr Reddy's said it will be going ahead with the product, despite Glenmark's clinical trial data being statistically insignificant.
BUSINESS
Opto Circuits says it received global orders to supply pulse oximeters, digital thermometers
The company said it has USFDA approvals, patents and technology for manufacturing of these products.
BUSINESS
Roche's Tocilizumab fails to meet primary end points for COVID-19 associated pneumonia
However, Roche said there was a positive trend in time to hospital discharge in patients treated with Actemra. The median time to discharge or ‘ready to discharge’ for Actemra was 20 days and for placebo was 28 days.
BUSINESS
How Donald Trump's executive orders to lower prescription drug prices will impact Indian drugmakers
Of the four orders, the one allowing the US government to pay the lowest price available in economically comparable countries for Medicare Part B drugs could particularly impact Indian companies
BUSINESS
Explainer: How IIT-Kharagpur's low-cost COVID-19 testing device works
The equipment developed by teams from Microfluidic Lab and School of Bioscience at IIT-Kharagpur will cost about Rs 2,000 on a pilot scale, compared to the RT PCR machine costing Rs 15 Lakh.
BUSINESS
When intensive care was necessary but lost out to a breathless rush
In Part 3 of our series on ventilators for Covid-19 patients, we look at how quality, training, service and support may have been given short shrift in the rush to make thousands of the breathing machines
BUSINESS
L&T says it will take few more quarters for normalcy in business operations to return
The company said it had lost about Rs 12,500 crores in revenue in Q1FY21 and declined to give guidance on order book, EBITDA and revenue citing uncertainity.
BUSINESS
Anatomy of a ventilator procurement order: How arbitrary changes to specifications led to delays and cost overruns
In Part-2 of our series on ventilators for COVID-19 patients, we look at the challenges Skanray Technologies, a Mysore-based medical devices company, faced as it scrambled to fulfil an order for 30,000 units in partnership with BEL and DRDO
BUSINESS
Hype or hope? Oxford COVID-19 vaccine trial data is expected today — what we know so far
The data will be published in British peer-reviewed medical journal the Lancet.
BUSINESS
Ventilators for COVID-19 patients Part-1: How domestic manufacturers went from exuberance to despair in 3 months
Shortage of critical-care equipment leads govt to invest Rs 2,000 crore to encourage domestic manufacturing. As companies jump into the fray and expand capacity, the nature of treatment and ventilators changes. With no fresh orders and a ban on exports, companies are in a spot.
BUSINESS
DCGI pulls up Glenmark for false claim on Favipiravir
DCGI issued notices based on a representation by a Member of Parliament (MP), who complained about the cost of the drug and the false claims.
BUSINESS
If Rouhani's COVID-19 numbers are true, Iran is heading for herd immunity
So what this possibly means is that Iran may not need a COVID-19 vaccine - generally considered as fastest and surest way to reach herd immunity.
BUSINESS
Exclusive | Zydus Cadila expects to launch Remdesivir in August: Chairman Pankaj Patel
Chairman Pankaj Patel said Zydus Cadila has potential to produce as high as 3-4 lakh doses a month.
BUSINESS
Pankaj Patel expects Zydus Cadila's potential COVID-19 vaccine to hit market by early 2021
"We are expecting the phase-1 and phase-2 studies to be completed in 3 months," Pankaj Patel said in an interview to Moneycontrol.
BUSINESS
COVID-19 treatment | Zydus Cadila gets Mexican drug regulator’s nod to test PegInterferon alfa-2b
Pegylated Interferon alfa-2b, is an old drug sold by Zydus under brand name PegiHepTM in India since 2011 for the treatment of Hepatitis B and C with 1.5 lac doses being administered.
BUSINESS
Explained: Why is Biocon's COVID-19 drug Itolizumab kicking up a controversy?
The critics are pointing to the small size of the clinical trial, exemption of Phase-3 trial, use of the drug as off-label for COVID-19, and making claims to the press before data is published in a peer-reviewed journal.
BUSINESS
Zydus Cadila begins human trials of its potential vaccine for coronavirus
The company said that Zydus has already manufactured clinical GMP batches of the vaccine candidate and plans to initiate the clinical trials in July 2020 across multiple sites in India in over 1000 subjects.
BUSINESS
Rising inventory, falling prices spook PPEs, sanitizer makers who jumped into COVID-19 bandwagon
According to Association of Indian Medical Device Industry (AiMeD) The capacity before onset of COVID-19 pandemic was 6.24 million units per annum to 250.98 million pieces per annum which is 43 times by end of by end of June.
BUSINESS
Biocon's partner Equillium plans Itolizumab's global clinical trial for COVID-19
Biocon has out-licensed Itolizumab to US-based biotech firm Equillium in 2017 for development in the US and Canada. Equillium has been awarded ‘fast track’ and ‘orphan drug’ designations for the molecule in both prevention and treatment of graft-versus-host disease by the USFDA.
BUSINESS
Coronavirus treatment | Cipla ramps up remdesivir capacity to meet surge in demand
Cipla also launched a dedicated 24x7 helpline and email channel to support patient access to these critical drugs exclusively during this pandemic outbreak.
BUSINESS
Pharma wrap: WHO adds airborne transmission to modes of coronavirus spread; but is it coming too late?
Airborne transmission allows a virus to enter the upper and lower respiratory tracts.
BUSINESS
Ajay Piramal says liquidity isn't a problem for good NBFCs
Piramal sees a 'U' shaped one, which is more gradual than a 'V' shaped recovery
BUSINESS
Indian pharma market contracts nearly 6% in Q1FY21
Chronic segment that includes drugs for cardiovascular, diabetes, and neuro saw a slump in sales in Q1FY21 due to pre-emptive buying in March
BUSINESS
Bharat Biotech COVID-19 vaccine: Testing underway at CDL-Kasauli, volunteer enrolment begins
Once CDL clears the batches, the vaccine candidate will be given to human volunteers within a day or two as part of Phase I and II human clinical trials.
